Aranesp Use In Chemotherapy Anemia Will Be Evaluated By M.D. Anderson
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
University of Texas’ M.D. Anderson Cancer Center expects this fall or early next year to evaluate possible pre-approval use of Amgen’s Aranesp (darbepoetin alfa) for chemotherapy-related ane